

BULLETIN

CANADIAN SOCIETY FOR IMMUNOLOGY

SOCIÉTÉ CANADIENNE D'IMMUNOLOGIE

SEPTEMBER 1992

V. 23, No. 2

0068-9653

Bulletin: Editor – Rédacteur: K. Hayglass, Ph.D., Dept. Immunology, University of Manitoba, Winnipeg, MB, R3E 0W3

CHANGES

We all like to keep in touch with what is going on at other Institutions. Contributions concerning trainees who have completed their degree/PDF, new faculty, and retirements as well as other items of general interest are invited. Please send information to the Editor c/o the address listed on the cover.

Politique éditoriale: Les membres réguliers et les membres étudiants de la SCI/CSI sont encouragés à soumettre des textes pour publication dans le Bulletin. Comme la plupart des membres sont capables de lire aussi bien le français que l'anglais avec une facilité suffisante, les auteurs pourront s'exprimer dans l'une ou l'autre langue. En accord avec la politique mise en place sous la direction du Dr. Fournier, les articles seront publiés dans la langue utilisée par l'auteur. Le Bulletin sera publié en septembre, décembre et mars. La date de tombée pour la réception d'un article à paraître dans le prochain numéro sera le 15 jour du mois précédant, soit trois semaines avant la date effective de parution. Les contributions ainsi que tout avis de changement d'adresse devront être adressés à: Kent T. HayGlass, Department of Immunology, University of Manitoba, 730 William Ave., Winnipeg, Man. R3E 0W3. Numéro de Téléphone: 204 788 6793. Numéro de télécopieur: 204 772 7924.

Editorial policy: Contributions from Full or Student members of the Society are encouraged. As most members are capable of reading English and French with reasonable facility, the choice of language of submission is left to each contributor. Items will be published in the language(s) in which they are contributed. The Bulletin will be published in September, December and March. Submissions may be made at any time. The deadline for receipt of copy is the 15th of the month prior to publication. Submissions, or address corrections, should be sent to: Kent T. HayGlass, Department of Immunology, University of Manitoba, 730 William Ave, Winnipeg, Man. R3E 0W3. Phone 204 788 6793. FAX 204 772 7924.

Dalhousie University

Department of Microbiology

NEWSFLASH: The Department of Microbiology has recently gained University Senate approval to change its name to the Department of Microbiology and Immunology! This is the culmination of many months of effort by members of the Immunology Group and the Microbiology Department who recognized that the current strength in Immunology within the Department justified such a name change. As a consequence, undergraduate students may now choose to specialize in the area of Immunology while an "Immunology Stream" has already been established for graduate students in the M.Sc. or Ph.D. programs who wish to pursue research careers in Immunology. Clearly this bodes well for the future of immunology at Dalhousie University.

In the past year the Immunology Group at Dalhousie University has been strengthened by the arrival of Dr. Andrew Stadnyk, who trained at McMaster University and the Seattle Biomedical Research Institute, and Dr. Tim Lee from the University of Calgary. Dr. Stadnyk is interested in the regulation of epithelial cell function by cytokines expressed in the normal and inflamed rat intestine while Dr. Lee is studying regulation of the IgE response during *Ascaris* infection. Both of these researchers have successfully established active research programs and are affiliated with the Department of Microbiology.

New research initiatives continue to be spawned within the Immunology Group. Dr. Tim Lee has organized a multidisciplinary group of researchers to examine the cellular and molecular basis of the development of specific immune tolerance to transplantation antigens with specific reference to the role of the liver in immune regulation. This group consists of Drs. Hinrich Bitter-Suermann (Surgery), Ron Carr (Medicine and Microbiology), David Hoskin (Microbiology), Tom Issekutz (Pediatrics and Microbiology), Tim Lee (Microbiology and Surgery), Terry Peterson (Medicine), and Jim Wright (Pathology). The ultimate aim of the group is to apply knowledge gained from allograft experiments performed in animal models to the clinical problem of human islet cell transplantation.

David W. Hoskin
Regional Correspondent



Dalhousie University

President's Report - Federation Board Meetings

As president of the CSI, I attended the Board Meetings of the Canadian Federation held in Victoria in conjunction with the annual Federation scientific meeting June 17-21, 1992. I also attended the program committee meeting although, as you all know, we do not actively participate in the Federation scientific meeting, instead having our own annual scientific meeting. I summarize below a few highlights which may be of interest to the membership. More details will be reported in the Federation newsletter.

1. Federation Budget (1993, proposed)

	Income	Expenditure	Profit (Loss)
Annual Meeting	160,000	144,000	16,000
Newsletter	5,000	32,000	(27,000)
Fees	165,000	1,000	164,000
Financial Management	4,000	27,000	(23,000)
Public Awareness of Science	0	47,000	(47,000)
Science Policy	0	83,000	(83,000)
		Net Gain (Loss)	0

This budget is directly comparable to that of last year. Note that there is no increase in fees and that the Federation annual meeting generates a small profit so that all our contributions go into the other activities of the Federation.

2. Science Policy (Science Policy Officer - Clément Gauthier)

Although the experiment is necessarily uncontrolled, one gets the impression that Federation science policy initiatives are having some effect and that we should continue to support them.

3. Federation annual scientific meeting

The program has been vastly improved over the last few years due to a coordinated planning process being organized by W. Bridger (University of Alberta). Each year's program is built around a small number of themes for which first class symposia are organized. However, I feel it is premature for us to consider abandoning our own separate meeting and rejoining the Federation meeting.

REPORT ON I.U.I.S. GENERAL ASSEMBLY MEETING

BUDAPEST AUGUST 23, 1992

Michelle Letarte and I attended the I.U.I.S. (International Union of Immunological Societies) General Assembly on behalf of C.S.I. The primary job of the Assembly is to elect the I.U.I.S. Council for the next three years. The new executive is:

President	H. Metzger (U.S.A.) (replacing J.B. Natvig)
Vice President (President-elect)	T. Tada (Japan)
Secretary-General	K. James (U.K.) (replacing R. Arnon)
Treasurer	P. Niewenhuis (Netherlands) (replacing J.D. Naysmith)

In addition, 15 Council Members were elected, of which I am one.

Natvig has been very active as President. He has been active in encouraging the formation of regional federations in Africa and the Far East. He has been instrumental in starting a new I.U.I.S. - sponsored immunology journal called The Immunologist. Copies of this should be available at our 1993 Lake Louise meeting.

The next Congress (1995) will be in San Francisco. W. Paul is Secretary-General and P. Marrack is chair of the program committee.

The Congress after that (1998) will be in Delhi, India.

- Richard G. Miller

BOOK REVIEW

Encyclopedia of Immunology, edited by I.M. Roitt and P.J. Delves. North American edition published by Academic Press. 2032 pages in three hard cover volumes. Released June 1992. US\$395 until October 31, 1992, US\$450 thereafter. ISBN 0-12-226760-5.

When I started graduate school in 1979, there was a copy of a Dictionary of Immunology in the lab for those new to the discipline who were desperately seeking clarification of immunological jargon. My most striking memory of it is that, having been published some 3-4 years earlier, it never seemed to have entries for the terms I was looking for. ("What is the difference between a cytokine, lymphokine and interleukin?"). In the interim, immunological jargon has expanded exponentially, in parallel with the number of immunologists. What Immunology really needs is a comprehensive, up to date, compendium of where we stand. And now we have one.

The *Encyclopedia of Immunology* by Roitt and Delves (and some 700 odd co-authors) represents a most impressive accomplishment. Consisting of 600 entries over 2000 pages in three volumes, this encyclopedia is of value to fourth year honours students, post-docs, and senior faculty who may be older than most of the discoveries listed. Its organization is extremely user-friendly, with a complete list of entries at the beginning of each volume. Topics not deemed worthy of their own entries--and there are not many I could think of--are listed in a well organized and comprehensive index. Most entries have a cross-referenced list of related entries (which I found very useful) and suggestions for further reading (of more variable utility).

Such is the organization. The quality? I would rank it very high. My approach was to choose about a dozen entries related to my own research interests, and a dozen where I was on thin ice (ie. Zinc and the Immune System). As in any multi-authored work (and this is certainly the most multi-authored work I have ever seen), the quality varies with the author. However, almost without exception, it is very impressive. Roitt and Delves have obtained well thought out summaries from most of their contributors. Some consist of non-judgmental listings of all possible hypotheses without any indication as to which way the field is leaning at present. This of course has the effect of giving all hypotheses equal credibility, whether it be because they are supported by new data or because they come from a powerful lab that the contributor does not wish/dare to snub. Other entries provide clear, or in some cases subtle, indications of the contributor's bias backed up by a thoughtful discussion. Though such opinions may ultimately prove wrong, I think that this approach, judiciously done, provides the most useful entries. In less controversial areas, such as in Michael Sela's exceptionally well written and brief entry on Affinity vs. Avidity, it is easy to see why those who make history, do.

The cost? Well, it is 2,000 pages. Academic Press is pricing it at US\$395 until the end of October, 1992 at which time it becomes US\$450. In comparison to the cost of one order of reprints (if anyone still orders reprints) or a subscription to a journal coming from Europe, this is a good buy. Its value will be evident for years.

Reviewed by Kent T. HayGlass, University of Manitoba.

**President – Président:**

R. G. Miller, Ph.D.
Ontario Cancer Institute
500 Sherbourne St.
Toronto, Ontario M4X 1K9
(416) 924-0671 Ext. 4997
FAX: (416) 926-6529

Secretary-Treasurer – Secrétaire-Trésorier:

J. A. Wilkins, Ph.D.
Department of Medicine
University of Manitoba
Winnipeg, Manitoba R3E 0Y8
(204) 787-4020
FAX: (204) 787-2420

Vice-President – Vice-Président:

W. S. Lapp, Ph.D.
Department of Physiology
McGill University
Montreal, Quebec H3G 1Y6
(514) 398-4980
FAX: (514) 398-7452

Past-President – Président Sortant:

A. Froese, Ph.D.
Department of Immunology
University of Manitoba
Winnipeg, Manitoba R3E 0W3
(204) 788-6648
FAX: (204) 772-7924

FAX # (416) 926-6529

June 1, 1992

Dr. Kent HayGlass
Editor, CSI Bulletin
Department of Immunology
University of Manitoba
Winnipeg, MB R3E 0W3

Dear Kent:

The attached correspondence is reasonably self explanatory.

- 1) Letter written by me on behalf of CSI Council to Dr. D.W. Strangway, President of the University of British Columbia commenting on what appeared to be the arbitrary and unfair manner in which Dr. John Schrader was dismissed from his position as Director of the Biomedical Research Center and suggesting a solution.
- 2) Reply from Dr. Strangway.
- 3) Reply from Dr. Hung-Sia Teh, who is presently Acting Director of the Biomedical Research Center.

It would appear that the matter has been resolved and that UBC has adopted a course of action which should produce a fair solution for all concerned.

Yours sincerely,

Richard G. Miller
President

P.S. In my letter to Dr. Strangway, there is one error and one point which probably requires additional clarification. It is the Biomedical Research Center, not the Biotechnology Research Center. At the time of Dr. Schrader's arbitrary dismissal, the Biomedical Research Center was controlled by the Fox Foundation for Medical Research and not by the University of British Columbia.

Councillors – Conseillers

M. Letarte, Ph.D.
Hospital for Sick Children, Toronto
A. Greenberg, Ph.D.
University of Manitoba

M. Ratcliffe, Ph.D.
McGill University
L. Pilarski, Ph.D.
University of Alberta

J. Schrader, Ph.D.
Biomedical Res. Ctr. Vancouver
J. Reynolds, Ph.D.
University of Calgary

**President – Président:**

R. G. Miller, Ph.D.
Ontario Cancer Institute
500 Sherbourne St.
Toronto, Ontario M4X 1K9
(416) 924-0671 Ext. 4997
FAX: (416) 926-6529

Secretary-Treasurer – Secrétaire-Trésorier:

J. A. Wilkins, Ph.D.
Department of Medicine
University of Manitoba
Winnipeg, Manitoba R3E 0Y8
(204) 787-4020
FAX: (204) 787-2420

Vice-President – Vice-Président:

W. S. Lapp, Ph.D.
Department of Physiology
McGill University
Montreal, Quebec H3G 1Y6
(514) 398-4980
FAX: (514) 398-7452

Past-President – Président Sortant:

A. Froese, Ph.D.
Department of Immunology
University of Manitoba
Winnipeg, Manitoba R3E 0W3
(204) 788-6648
FAX: (204) 772-7924

FAX # (416) 926-6529

April 1, 1992

Dr. David W. Strangway
President & Vice Chancellor
University of British Columbia
6328 Memorial Road
Vancouver, BC V6T 1Z2

Dear Dr. Strangway:

Re: Biotechnology Research Center

Early last year, the Board of Directors of the Biotechnology Research Center decided not to renew the contract of their Founding Director, Dr. John Schrader, and his appointment terminated last summer. The reasons for this decision have never been publicly stated. It appears to have come as a great surprise and shock to the members of the Center.

The research of the Center has been primarily in the area of biotechnology applied to problems of immunological interest and has been well regarded by the Canadian immunological community. Indeed, Dr. Schrader was recently elected to be a Councillor of the Canadian Society for Immunology. By the criteria of publications and competitive research funding, the performance of the center would appear to be superior. An international Science Board recently came to the same conclusion. The people on this committee constitute an impressive list of leading international figures. Thus the Canadian immunology community was also surprised and shocked that Dr. Schrader's appointment was terminated. There is a widespread feeling in the Canadian immunology community that Dr. Schrader has been dealt with in an unfair and arbitrary manner.

I wrote to you last Nov. 7 expressing my personal concern about this matter. On March 14, the matter was discussed at the annual meeting of the Council of the Canadian Society for Immunology. Dr. Schrader was not present for this discussion. The Council unanimously agreed on the contents of this letter and that this letter should be published in our Bulletin.

...2/

Councillors – Conseillers

M. Letarte, Ph.D.
Hospital for Sick Children, Toronto
A. Greenberg, Ph.D.
University of Manitoba

M. Ratcliffe, Ph.D.
McGill University
L. Pilarski, Ph.D.
University of Alberta

J. Schrader, Ph.D.
Biomedical Res. Ctr. Vancouver
J. Reynolds, Ph.D.
University of Calgary

Bulletin: Editor – Rédacteur: K. Hayglass, Ph.D., Dept. Immunology, University of Manitoba, Winnipeg, MB, R3E 0W3

It is our understanding that, following recent events, the University of British Columbia now controls a majority on the Board of the Biotechnology Research Center. We feel that one way to resolve the outstanding issues would be for the University to hold an open search for the Director's position, according to the University's standard procedures. Dr. Schrader would be eligible to apply.

Yours sincerely,



Richard G. Miller
President

c.c. The Right Honourable
Mr. M. Harcourt
Premier
Province of British Columbia
Provincial Legislature
Victoria, B.C.

Dr. Alan Bernstein
Acting Chair, Science Board
Samuel Lunenfeld Research Institute
Mt. Sinai Hospital
Room 885, 600 University Avenue
Toronto, Ontario M5G 1X5

THE UNIVERSITY OF BRITISH COLUMBIA



Office of the President
6328 Memorial Road
Vancouver, B.C. Canada V6T 2B3
Tel: (604) 228-2121
Fax: (604) 228-3134

April 21, 1992

Dr. Richard G. Miller
President
Ontario Cancer Institute
500 Sherbourne Street
Toronto, ON
M4X 1K9

Dear Dr. Miller:

I am writing in reply to your letter of April 1, 1992 about the Biomedical Research Centre and its founding director, Dr. John Schrader.

One of the conditions the University of British Columbia attached to its agreement to take responsibility for the BRC was that the search for a new director be conducted under normal university policy and procedures. On March 14, Dr. Tom Perry, Minister of Advanced Education announced that the government of British Columbia had approved funding and the University of British Columbia would take responsibility for the BRC. Dr. Dan Birch, UBC's Provost, informed BRC staff that the search for a director would be initiated and that Dr. John Schrader would be eligible to apply.

Thank you for your interest.

Yours sincerely,

David W. Strangway
President

DWS/cp

THE UNIVERSITY OF BRITISH COLUMBIA



Department of Microbiology
#300 - 6174 University Boulevard
Vancouver, B.C. Canada V6T 1Z3
Tel: (604) 822-3308 Fax: (604) 822-6041

May 6, 1992

Dr. Richard G. Miller, President
Canadian Society for Immunology

Dear Rick,

Re: Biomedical Research Center

I am writing to clarify some of the misconceptions held by Canadian immunologists regarding the role of the University of British Columbia in the affairs of the Biomedical Research Center as evidenced by the contents of your letter dated April 1, 1992.

The Biomedical Research Center was founded and operated by the Terry Fox Medical Research Foundation and Wellcome Research Laboratories and was under their direction with no involvement of UBC. Wellcome's decision to withdraw from BRC was a policy decision and is unrelated to the performance of BRC since its inception. The decision not to renew Dr. John Schrader's contract as director was made by the Terry Fox Medical Research Foundation and not UBC.

Following the withdrawal of support by Wellcome of the BRC the more important issue at hand was to secure long term funding for BRC and preserve the integrity of BRC as a research institute. The Fox Board, in consultation with UBC, recruited one of the most respected scientists and administrators at UBC, Dr. Michael Smith, to tackle this difficult problem. As correctly pointed out in your letter the performance of the scientists at BRC during the past four years has been superior. Consequently, every effort was made by the senior UBC administration to ensure the continuing success of BRC. I am pleased to inform you that a deal has now been struck between the Government of BC, UBC, the Terry Fox Foundation, and Wellcome to transfer complete control of BRC to UBC as of April 1, 1992. Furthermore, the Government of BC has come through with funding for BRC for the next three years, with every intention of continuing support beyond this three year period. The BRC is now a bona fide research institute aimed at performing cutting edge research in immunology and the molecular basis of intracellular signalling and growth control. It does not have a time table to produce biomedical reagents for commercial purposes but conceivably the foresight of UBC in preserving this research institute whose primary focus is basic research will undoubtedly lead to the production of many useful biomedical drugs in a shorter period of time. The amount of funding secured is also sufficient for renovations and for increasing the number of scientists at BRC from seven to ten. During this transition period Dr. Schrader continues to be a member of the BRC, retains his laboratory in the BRC, and has university tenure in the Department

January 1993, Vol. 1, No. 1

The Immunologist

Official Organ of the
International Union
of Immunological Societies
(IUIS)

Dear Immunologists, Colleagues and Friends,

Here comes our new and first IUIS journal:
THE IMMUNOLOGIST.

We are pleased to inform you that an effort which has taken almost 3 years has now become a reality, IUIS finally has its own journal publication "THE IMMUNOLOGIST".

THE IMMUNOLOGIST is a new voice of the IUIS which is destined to present first class immunology in articles, reviews and discussions. In addition, it will serve as a forum for all matters which are of interest to the immunological community. It therefore provides unique opportunities to communicate directly with immunologists from all over the world, as well as a wide range of medical personnel and others working in the fields where applied immunology is making more and more impact.

THE IMMUNOLOGIST is being produced by Hogrefe and Huber, an international publisher, located in Seattle, Toronto, Bern and Göttingen.

In a very good collaboration with the publisher we are now able to offer your members a special rate. If they subscribe through your society, the price will only be US\$ 39.00 for 6 issues for 1993 which is a 43-50% discount compared to the usual individual price of US\$ 68.00 and US\$ 78.00 for institutions and libraries. It will be possible to offer this good arrangement for the subscriptions channelled through your society, thus making much lower handling charges.

INNOVATEURS À L'ÉCOLE

Ligne spéciale (613) 993-7597

Télécopieur (613) 941-2811

Qu'est ce que le programme «Innovateurs à l'école»?

- Initiative fédérale-provinciale-territoriale de coopération, le «Réseau des Innovateurs à l'école» aide et encourage les professionnels à visiter les écoles de leur communauté. Ils peuvent ainsi s'entretenir avec les étudiants et les enseignants ainsi que les sensibiliser aux possibilités d'études et de carrière en sciences et en technologie.

Pourquoi une telle initiative?


- Le Canada fait face en ce moment à une baisse des effectifs scolaires dans les programmes des sciences et de technologie aux niveaux collégial et universitaire. Pourtant, notre pays nécessite davantage de scientifiques, d'ingénieurs, de techniciens et de technologues pour hausser la compétitivité industrielle nationale.

Comment organiser une visite?

- Bien que les responsables du Réseau ne remboursent pas les dépenses encourues par les visites dans les écoles, ils fournissent des services et du matériel de soutien aux Innovateurs. Ces derniers doivent généralement planifier de deux à trois heures pour l'organisation d'une visite et la visite elle-même.



Pourquoi ne pas demander à un ami ou à un collègue ayant les qualités requises de joindre les rangs des Innovateurs?

 Industrie, Sciences et Technologie Canada / Industry, Science and Technology Canada

FORMULAIRE D'INSCRIPTION

Nom _____

Adresse au travail (numéro, rue, ville, province, code postal) _____

Téléphone au travail _____

Télécopieur _____

Profession _____

☐ J'aimerais recevoir la trousse d'entraînement «comment faire apprécier les sciences aux élèves»

Langue préférée

☐ Anglais ☐ Français

Quel groupe d'âge vous intéresse le plus?

☐ 8 à 11 ans (de la 3^e à la 6^e année)

☐ 12 à 14 ans (de la 7^e à la 9^e année)

☐ 15 ans et plus (10^e année et plus)

☐ N'importe quel âge

Qu'est-ce qui vous intéresse?

☐ Vous adresser à une classe

☐ Faire des démonstrations

☐ Participer à des journées de carrières

☐ Être juge à des expositions scientifiques

☐ Autre (veuillez préciser)

ISTC 2185 (3/92)

IST/IST-205-05074

FOR MORE INFORMATION, PLEASE CONTACT:

Hotline (613) 993-7597

Facsimile (613) 941-2811

INNOVATORS IN THE SCHOOLS

What is the "Innovators in the Schools Network"?

- The "Innovators in the Schools Network" is a cooperative federal/provincial/territorial initiative designed to aid and encourage professional scientists, engineers, technicians and technologists to visit schools in their community to talk to elementary and secondary students and teachers about studies and careers in science and technology.


Why the initiative?

- Canada faces a declining enrolment in science and technology related programs at the college and university levels at precisely the time when more scientists, engineers, technicians and technologists are needed to enhance our industrial competitiveness.

How to organize a visit?

- Visits normally take about 2-3 hours to arrange and complete. 25,000 volunteers are needed. Join us by completing this postage-paid registration form. While the Network does not compensate for costs incurred on school visits, support services and materials will be provided.



 Industry, Science and Technology Canada / Industrie, Sciences et Technologie Canada

REGISTRATION FORM

Name _____

Business Address (number, street, city, province, postal code) _____

Business Telephone _____

Facsimile _____

Occupation _____

☐ I would like to receive the training kit "Selling Science to Students"

Language Preference

☐ English ☐ French

Which age group would you like to address?

☐ 8 to 11 years old (grades 3 to 6)

☐ 12 to 14 years old (grades 7 to 9)

☐ 15 and over (grades 10 and above)

☐ Any age

Are you comfortable

☐ Addressing groups of students?

☐ Doing demonstrations?

☐ Participating in Career Days?

☐ Judging Science Fairs?

☐ Other (please specify)

Why not ask a qualified friend/colleague to become an Innovator, too?

ISTC 2185 (3/92)

IST/IST-205-05074